Anjiyoödem/Ürtikerli Hastaya Yaklaşım

Authors

Şengül Baran Yerlikaya

Synopsis

Urticaria and angioedema are localized skin manifestations resulting from vasodilation and plasma extravasation in the dermis and subcutaneous tissues. Conditions lasting less than six weeks are classified as acute, whereas those persisting for more than six weeks are defined as chronic urticaria. While acute cases are typically triggered by allergens or infections, chronic spontaneous urticaria is mostly idiopathic. Diagnosis relies fundamentally on a detailed medical history and physical examination; routine laboratory evaluations such as complete blood count, CRP, ESR, TSH, and renal and liver function tests are generally sufficient. In differential diagnosis, anaphylaxis must be excluded first, while conditions like serum sickness, hereditary angioedema, and urticarial vasculitis should be considered. Treatment is centered on avoiding triggering factors, symptomatic management, and treating underlying conditions. Second-generation non-sedating H1 antihistamines represent the first-line therapy, with dosages scalable up to fourfold in refractory cases. Short-course systemic glucocorticoids can be added for severe or vasculitic presentations unresponsive to antihistamines. In chronic cases resistant to standard therapies, omalizumab emerges as a key fourth-line biological option. Additionally, patients should avoid tight clothing, friction, intense exercise, and exacerbating medications such as NSAIDs or ACE inhibitors.

References

Zuberbier T, Aberer W, Asero R, et al: The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69:868-87

Wedi B: Urticaria. J Dtsch Dermatol Ges 2008; 6:306-17.

Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007;87(3):196-205.

Magerl MA, Altrichter S, Boodstein N, Güzelbey O, Keßler B, Krause K et al. Urticaria – classification and strategies for diagnosis and treatment. CME Dermatol 2008;3(1):2-18.

Bernstein J, Lang D, Khan D. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1277.

Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869e873.

Sanchez-Borges M, Asero R, Ansotegui IJ, et al: Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5:125-47.

Zuberbier T, Maurer M. urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm venereol. 2007; 87:196-205

Kaplan AP. Angioedema. World Allergy Organ J 2008;1(6):103-13

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B et al. The EAACI/GA²LEN/EDF/WAo guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414.

Kuemmerle-Deschner JB, ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2017; 76:942-7.

Marzano AV, Tavecchio S, Venturini M, Sala R, Calzavara-Pinton P, Gattorno M: Urticarial vasculitis and urticarial autoinflammatory syndromes. Gıtal Dermatol Venereol 2015;150: 41

Katherine N. Cahill; Joshua A. Boyce, Harrison 20th Edition, Chapter 345: Urticaria, Angioedema, and Allergic Rhinitis, 2498-2499.

Ortonne JP: Chronic urticaria: a comparison of management guidelines. Expert opin Pharmacother. 2011; 12:2683-93.)

Akoglu G, Atakan N, Cakir B, Kalayci o, Hayran M. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res. 2012; 304:257-262.

Wong jT, nagy CS, Krinzman Sj, Maclean jA, Bloch Kj. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. j Allergy Clin Immunol. 2000;105:997 1001.

Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol. 2003; 28:123-7.

Díaz jara M, pérez Montero A, Gracia Bara MT, Cabrerizo S, Zapatero l, Martínez Molero MI. Allergic reactions due to ibuprofen in children. Pediatr Dermatol. 2001; 18:66-7.

Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal antiinflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136: 245-51.

Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol. 2015; 40:399-403.

Haas n, Toppe E, Henz BM. Microscopic morphology of different types of urticaria. Arch Dermatol. 1998; 134:41-6.

RY, Curry A, pesola GR, Knight Rj, lee HS, Bakalchuk l, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000; 36:462-8.

Zuberbier T, Asero R, Bindslev-jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)lEn/EDF/WAo guideline: management of urticaria. Allergy. 2009; 64:1427-43.

Zuberbier T. A Summary of the new International EAACI/GA2lEn/EDF/WAo Guidelines in urticaria. World Allergy organ j. 2012;5 (1):S1-5.

Serrano-Candelas E, Martinez-Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016;46(1):92-102.

Maurer M1, Rosén K, Hsieh Hj, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin j, Kaplan A, Casale T. omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. n Engl j Med. 2013;368:924-35.

Published

May 20, 2021

License

License